The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma

Swiss Med Wkly. 2016 Feb 22:146:w14279. doi: 10.4414/smw.2016.14279. eCollection 2016.

Abstract

Cutaneous melanoma is the most deadly cutaneous neoplasm. In order to guide treatment decisions and follow-up of melanoma patients, guidelines for the management of melanoma in Switzerland were inaugurated in 2001 and revised in 2006 and 2016. Recent data on surgical and medical treatments from randomised trials necessitated modification of the treatment and follow-up recommendations.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Chemotherapy, Adjuvant
  • Dacarbazine / analogs & derivatives
  • Dacarbazine / therapeutic use
  • Dermatologic Surgical Procedures
  • Humans
  • Imidazoles / therapeutic use
  • Indoles / therapeutic use
  • Ipilimumab
  • Lymph Node Excision
  • Melanoma / pathology
  • Melanoma / therapy*
  • Neoplasm Staging
  • Nivolumab
  • Oximes / therapeutic use
  • Practice Guidelines as Topic
  • Radiotherapy, Adjuvant
  • Sentinel Lymph Node Biopsy
  • Skin Neoplasms / pathology
  • Skin Neoplasms / therapy*
  • Sulfonamides / therapeutic use
  • Switzerland
  • Temozolomide
  • Vemurafenib

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Imidazoles
  • Indoles
  • Ipilimumab
  • Oximes
  • Sulfonamides
  • Vemurafenib
  • Nivolumab
  • Dacarbazine
  • dabrafenib
  • Temozolomide